Novel treatment paradigms for metastatic uveal melanoma

Uveal melanoma (UM) is the most common primary intraocular malignancy, accounting for 85 to 95% of primary ocular malignancies and 3 to 5% of all melanoma cases. While patients with metastatic UM continue to represent a population in need of better outcomes, meaningful progress has been made with respect to deepening our understanding of the disease biology and development of novel therapeutics, including the first regulatory approval of a systemic agent shown to improve survival. Innovative molecular and immunotherapy approaches that leverage biologic vulnerabilities in UM cells and specific immunosuppressive pathways driving disease progression in the liver may support further advances. We hope this special issue of Cancer Gene Therapy proves to be a valuable resource for those in the scientific and medical communities committed to improving UM patient outcomes.

collection image